3,4-二甲基-2,5-二氢吡喃-6,6-二羧酸 | 57668-94-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 中文名称: 3,4-二甲基-2,5-二氢吡喃-6,6-二羧酸
• 英文名称: 4,5-dimethyl-3,6-dihydro-2H-pyran-2,2-dicarboxylic acid
• 英文别名: 4,5-dimethyl-3,6-dihydro-pyran-2,2-dicarboxylic acid；4,5-Dimethyl-3,6-dihydro-pyran-2,2-dicarbonsaeure；3,6-dihydro-4,5-dimethyl-2H-pyran-2,2-dicarboxylic acid；3,4-Dimethyl-5,6-dihydro-1,2-pyran-dicarbonsaeure-(6,6)；3,4-dimethyl-2,5-dihydropyran-6,6-dicarboxylic acid
• CAS: 57668-94-7
• 化学式: C₉H₁₂O₅
• 分子量: 200.191
• InChiKey: IJXWYMXOQFLCEF-UHFFFAOYSA-N

物化性质

• 沸点：
  413.7±45.0 °C(Predicted)
• 密度：
  1.337±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3,4-二甲基-2,5-二氢吡喃-6,6-二羧酸 在 吗啉 、 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 吡啶 、 苯 为溶剂， 反应 36.0h， 生成
  参考文献：
  名称：

  ACAT inhibitors derived from hetero-Diels-Alder cycloadducts of thioaldehydes

  摘要：

  Acyl-CoA:cholesterol acyltransferase (ACAT) is the enzyme largely responsible for intracellular cholesterol esterification. A systemic inhibitor of ACAT is believed to be able to slow or even reverse the atherosclerotic process. Towards that goal, a series of cyclic sulfides, derived from the hetero-Diels-Alder reaction of thioaldehydes with 1,3-dienes, and bearing carboxamide substituents, were prepared and evaluated for in vitro (in several tissues and species) and ex vivo ACAT inhibition. Minor changes in subsequent structure were found to have a significant effect in optimization of the biological activity of this series of compounds. Copyright (C) 1996 The DuPont Merck Pharmaceutical Company.

  DOI：

  10.1016/0968-0896(96)00143-5
• 作为产物：
  描述：

  4,5-dimethyl-3,6-dihydro-pyran-2,2-dicarboxylic acid diethyl ester 在 氢氧化钾 作用下， 以 四氢呋喃 为溶剂， 反应 10.0h， 以99%的产率得到3,4-二甲基-2,5-二氢吡喃-6,6-二羧酸
  参考文献：
  名称：

  ACAT inhibitors derived from hetero-Diels-Alder cycloadducts of thioaldehydes

  摘要：

  Acyl-CoA:cholesterol acyltransferase (ACAT) is the enzyme largely responsible for intracellular cholesterol esterification. A systemic inhibitor of ACAT is believed to be able to slow or even reverse the atherosclerotic process. Towards that goal, a series of cyclic sulfides, derived from the hetero-Diels-Alder reaction of thioaldehydes with 1,3-dienes, and bearing carboxamide substituents, were prepared and evaluated for in vitro (in several tissues and species) and ex vivo ACAT inhibition. Minor changes in subsequent structure were found to have a significant effect in optimization of the biological activity of this series of compounds. Copyright (C) 1996 The DuPont Merck Pharmaceutical Company.

  DOI：

  10.1016/0968-0896(96)00143-5

文献信息

• Derivatives of cyclic ethers and sulfides for the treatment of
  申请人：The Du Pont Merck Pharmaceutical Company

  公开号：US05491152A1

  公开（公告）日：1996-02-13

  The present invention provides compounds of Formula I, ##STR1## or a pharmaceutically acceptable salt forms thereof, which are inhibitors of acyl-Coenzyme A: cholesterol O-acyltransferase (ACAT), pharmaceutical compositions containing such compounds, processes for the preparation of such compounds, and the use of such compounds as antihypercholesterolemic and/or antiatherosclerotic agents.

  本发明提供了I式化合物，##STR1##或其药物可接受的盐形式，它们是酰基辅酶A：胆固醇O-酰基转移酶（ACAT）的抑制剂，包含这种化合物的制药组合物，制备这种化合物的方法，以及将这种化合物用作抗高胆固醇和/或抗动脉粥样硬化药剂的用途。
• Achmatowicz; Zamojski, Croatica Chemica Acta, 1957, vol. 29, p. 269,272
  作者：Achmatowicz、Zamojski

  DOI：——

  日期：——
• US5491152A
  申请人：——

  公开号：US5491152A

  公开（公告）日：1996-02-13
• ACAT inhibitors derived from hetero-Diels-Alder cycloadducts of thioaldehydes
  作者：Richard G. Wilde、Jeffrey T. Billheimer、Sandie J. Germain、Elizabeth A. Hausner、Paul C. Meunier、Deborah A. Munzer、Janet K. Stoltenborg、Peter J. Gillies、Deborah L. Burcham、Shiew-Mai Huang、John D. Klaczkiewicz、Soo S. Ko、Ruth R. Wexler

  DOI：10.1016/0968-0896(96)00143-5

  日期：1996.9

  Acyl-CoA:cholesterol acyltransferase (ACAT) is the enzyme largely responsible for intracellular cholesterol esterification. A systemic inhibitor of ACAT is believed to be able to slow or even reverse the atherosclerotic process. Towards that goal, a series of cyclic sulfides, derived from the hetero-Diels-Alder reaction of thioaldehydes with 1,3-dienes, and bearing carboxamide substituents, were prepared and evaluated for in vitro (in several tissues and species) and ex vivo ACAT inhibition. Minor changes in subsequent structure were found to have a significant effect in optimization of the biological activity of this series of compounds. Copyright (C) 1996 The DuPont Merck Pharmaceutical Company.